Percutaneous Coronary Intervention Clinical Trial
Official title:
Safety Evaluation of Intracoronary Infusion of Extracellular Vesicles in Patients Following Coronary Stent Implantation (EV-CSI)
The purpose of this study is to determine the safety of using a biological drug called PEP in people who have had a coronary stent placed. A biological drug is a substance that is made from a living organism or its products (parts). In this case, PEP is made of certain parts of blood from living blood donors obtained from a certified blood bank. PEP comes in a powder form and is mixed with heparinized saline (a solution used to prevent clots in catheters) to create a solution that can be injected. The investigators want to see if PEP can be used to stop or slow heart damage.
Patients who undergo Percutaneous Coronary Intervention (PCI) will be treated with a single dose of PEP within 20 minutes after stent placement or post-dilation (whichever is last). Subjects will be screened at the time of emergency room presentation. Subjects will be treated in the cardiac catheterization laboratory where the PCI will be completed and PEP will be administered. Subjects will be followed for one year after PEP administration through clinic visits. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
| Not yet recruiting |
NCT05669222 -
The FAVOR V AMI Trial
|
N/A | |
| Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
| Recruiting |
NCT05240781 -
Zotarolimus vs Sirolimus Eluting Stent in High Bleeding Risk
|
N/A | |
| Recruiting |
NCT03378934 -
Anti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention
|
Phase 4 | |
| Not yet recruiting |
NCT06025071 -
Residual Inflammatory Risk-Guided colcHicine in Elderly Trial
|
Phase 4 | |
| Withdrawn |
NCT04043091 -
Coronary Angiography in Critically Ill Patients With Type II Myocardial Infarction
|
N/A | |
| Completed |
NCT03085823 -
The All-comers Sirolimus-coated Balloon European Registry
|
||
| Completed |
NCT02837744 -
Studying Hemostatic Effect of Axiostat® Dressing on Radial Access After Percutaneous Procedure
|
||
| Completed |
NCT02044146 -
A Pharmacodynamic Study of a Personalized Strategy for P2Y12 Inhibition Versus Ticagrelor in Reducing Ischemic and Bleeding Risk
|
Phase 2/Phase 3 | |
| Completed |
NCT03131271 -
Effect of Ice Bag Application to Femoral Region on Pain in Patients Undergoing Percutaneous Coronary Intervention
|
N/A | |
| Completed |
NCT01156571 -
A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)
|
Phase 3 | |
| Completed |
NCT01135667 -
Prasugrel Versus Double Dose Clopidogrel to Treat Clopidogrel Low-responsiveness After PCI
|
Phase 4 | |
| Unknown status |
NCT00751491 -
Clopidogrel Versus Adenosin in Non Urgent Percutaneous Coronary Intervention (PCI)
|
Phase 3 | |
| Completed |
NCT00725868 -
Blood Endothelium Biomarkers to Predict Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention
|
N/A | |
| Completed |
NCT03708588 -
Chewed Versus Integral Pill of Ticagrelor
|
Phase 4 | |
| Completed |
NCT04163393 -
R-One Efficiency For PCI Evolution With Robotic Assistance
|
N/A | |
| Recruiting |
NCT05554588 -
Intrathrombus Thrombolysis Versus Aspiration Thrombectomy During Primary PCI
|
N/A | |
| Recruiting |
NCT06080919 -
Plaque Modification And Impact On Microcirculatory Territory After Drug-Coated Balloon Percutaneous Coronary Intervention (PLAMI).
|
N/A | |
| Recruiting |
NCT05353140 -
LAAO Versus NOAC in Patients With AF and PCI
|
N/A |